Based on the study, published in the July 2011 Cancer Research (Priority Reports), researchers are suggesting a new approach to colon cancer treatments targeting multiple genes and pathways simultaneously. Current cancer treatments target just one or two known cancer-driver genes believing this would be beneficial to patients. While patients may get transient tumor burden reduction, almost universally tumor growth returns.
|Dr. Jerry Shay|
The UT Southwestern research contradicts previous thinking that only a few mutated genes are important in the development of cancerous tumors.
“The ways we’ve been treating patients up to now is to just go after one target when we should be going after three to four different pathways simultaneously,” said Dr. Jerry W. Shay, vice chairman and professor of cell biology at UT Southwestern.
Under the old model, scientists believed there were 151 candidate genes and that mutations in just eight to 15 of them would lead to cancer. There were 700 other genes classified as passenger genes whose mutations were incidental to cancer growth.
“Those numbers are dead wrong,” Dr. Shay said. According to UT Southwestern’s research, there are 65 candidate genes and at least five passenger genes whose mutations play significant roles in cancer development. Inactivating the function of any of these tumor-suppressing genes led to a key step in cancer development called anchorage-independent growth, meaning cells piled up on top of each other rather than aligning neatly.
The next step is further research to classify more accurately which genes drive cancer and which are merely passengers.
Other UT Southwestern researchers involved in the study were lead author Ugur Eskiocak, student research assistant in cell biology; Dr. Sang Bum Kim, postdoctoral researcher in cell biology; Peter Ly, student research assistant in cell biology; Dr. Andres Roig, assistant professor of internal medicine; Dr. Sebastian Biglione, a former postdoctoral fellow in cell biology; Crystal Cornelius, research assistant in cell biology; Dr. Woodring Wright, professor of cell biology and internal medicine; and Dr. Michael White, professor of cell biology.
One researcher from UT M.D. Anderson Cancer Center also participated. The study was supported by grants from NASA and the Cancer Prevention and Research Institute of Texas.
Visit www.utsouthwestern.org/cancer to learn more about UT Southwestern’s clinical services in cancer.
Media Contact: Debbie Bolles